Purpose To evaluate whether ultrasound-guided injection of hyperosmolar dextrose for treatment of patellar tendinopathy decreases pain scores and normalises the appearance of the patellar tendon on ultrasound. Methods Subjects were referred from primary care clinics and failed conservative treatment. Subjects received a diagnostic ultrasound examination, then ultrasound-guided injection of 25% dextrose with lidocaine into the area of tendinopathy until they were satisfi ed with treatment. The primary outcome measure was a three-part visual analogue scale (VAS; baseline and mean of 45 weeks after start of treatment) for pain at rest, activities of daily living (ADL) and during sport. Secondary outcomes included segmental ultrasound examinations assessing tendon hypoechogenicity (area and severity score), neovascularity (severity score) and the presence or absence of intratendinous tearing and calcifi cation, irregularities of cortical bone and thickness. Results 47 consecutive referrals were included. Subjects received a mean of four (±3) injection sessions. At mean 45 weeks post-enrollment, subjects reported a reduction in pain across the three VAS items (rest 38.4±25-18.7±18.4; ADL 51.1±22.9-25.8±20.1; sport 78.1±15.7-38.8±26.1; p<0.01). There was improvement in neovascularity following the dextrose injection. A signifi cant correlation between hypoechogenicity severity scores and pain at follow-up is reported. Conclusion There was a reduction in pain and an improvement in ultrasound appearance following ultrasound-guided dextrose injections for refractory patellar tendinopathy. An improved hypoechoic appearance of the tendon was associated with decreased pain scores, suggesting that dextrose injections may modify patellar tendinopathy at the tissue level and that fi brillar changes may play a role in tendon nociception.
Patellar tendinopathy ('jumper's knee') is a painful and disabling condition caused by chronic repetitive stress of the proximal patellar tendon at its insertion on the inferior pole of the patella. 1 It is particularly prevalent in athletic populations, affecting 40-50% of persons in those sports requiring repetitive, explosive power from the knee extensors, including basketball, volleyball, soccer and track and fi eld. 2 Patellar tendinopathy is associated with signifi cant impact on quality of life, loss of function and changes on ultrasound imaging of the tendon. 3 Whereas current therapy is associated with the resolution of patellar tendinopathy for many, patellar tendinopathy can become chronic in a subset of patients, severely impacting an individual's long-term participation in sport. Half of all cases of patellar tendinopathy managed conservatively become chronic and are prone to recur; an estimated 29% of patients become candidates for surgery upon failing conservative treatment. 4 5 One prospective case-control analysis of athletes with patellar tendinopathy reported that more than 50% of patients with patellar tendinopathy ended their sports career as a result of this injury. 6 No widely used therapy for patellar tendinopathy addresses the underlying tissue degeneration now understood to be the hallmark of overuse tendinopathies. 7 Prolotherapy is an injection therapy used to treat chronic musculoskeletal pain including tendinopathies. 8 It has been hypothesised to stimulate healing of chronic soft tissue injury by a local infl ammatory response to therapy, although the precise mechanism is unclear. 9 Prolotherapy using hypertonic dextrose has been reported to reduce pain associated with chronic tendinopathies at the Achilles tendon, plantar fascia and groin. [10] [11] [12] Dextrose prolotherapy has also been associated with ultrasound-based changes associated with tissue healing in overuse tendinopathy. 13 The histological, sonographic and clinical presentation of tendinopathy appears similar in cases at the Achilles, common elbow extensor and patellar tendons, 2 14 15 as well as the plantar fascia, 12 and they are thought to share underlying degenerative pathophysiology. 16 Although dextrose prolotherapy has shown clinical effi cacy in reducing tendinopathic pain at other locations, it has not yet been assessed as a treatment for patellar tendinopathy. 10 12 13 Therefore, given the lack of a defi nitive treatment option for infrapatellar tendinopathy that is non-responsive to conservative measures, we conducted a prospective case series to address the hypotheses that ultrasound-guided dextrose injection therapy for patellar tendinopathy would be associated with a reduction in pain and ultrasound changes in tendon architecture consistent with tendon healing. A secondary hypothesis is that pain and sonographic features of tendinopathy are positively correlated following dextrose injection.
MATERIALS AND METHODS Participants
The diagnosis of patellar tendinopathy was made clinically on the basis of self-reported pain and palpatory tenderness along the length of the patellar tendon at its proximal insertion directly at the inferior pole of the patella, and radiologically based on the presence of one or more of the following abnormalities: hypoechoic regions; discrete anechoic areas or intratendinous tears and neovascularisation. Participants in the study were referred from August 2003 to February 2009 by board-certifi ed sports medicine specialists in the local Vancouver area after failing standard-of-care therapy including: eccentric drop-squats (n=22); supervised general physiotherapy (n=16); non-steroidal anti-infl ammatory medication (n=9); general exercises for knee extension and for the lower extremity (n=8); extracorporeal shock wave therapy (n=4); foot orthoses (n=4); knee braces (n=4); acupuncture (n=2); chiropractic manipulation (n=1) and cortisone injections (n=1). The athletic backgrounds of the study population were varied: fi ve performed their sport at a national level of competition (n=1, skiing; n=2, running/track; n=1, spring board diving; n=1, ballet dance), seven were non-athletes (non-athletic activities not documented) and the remainder were active on a recreational basis.
The study protocols received ethical approval from the University of British Columbia Clinical Review Board.
Ultrasound examination
The ultrasound examination and the injection procedure were performed by the same radiologist (AW) with 20 years experience in musculoskeletal radiology and research. The patellar tendon and surrounding tissue was examined with the patient lying supine and the knee in a straight position. The ultrasound examination was performed using a Philips HDI 5000 ultrasound machine (Philips, Phillips USA, Bothell, Washington, USA ) using both a 5-12 MHz and 7-15 MHz linear array high resolution transducer/receiver. The tendon in its entirety was examined in the longitudinal and transverse planes, with tendon thickness recorded as the greatest distance spanning the tendon in the anterior-posterior plane. Care was taken to image the patellar tendon parallel with the fi bres in the longitudinal plane and perpendicular to the fi bres in the transverse plane to avoid anisotropic artifacts. 17 18 Colour fl ow Doppler (6.6 MHz) was used to diagnose the extent of neovascularity on a modifi ed Öhberg 0-3 ordinal scale, on which '0' represented no blood vessels visible, '1' indicated mild (one to two vessels extending into the tendon), '2' moderate (three to four neovessels) and '3' marked (more than four vessels extending into the tendon) neovascularity ( fi gure 1 ). 19 Hypoechoic regions were documented in two ways. The fi rst measured the cross-sectional area of the hypoechoic region in square millimetres using the free-hand measurement tool in Inteleviewer radiological software (version 3.5.1.P98, 2002; fi gure 2 ). 20 The second evaluation of hypoechoic areas (or echotexture rating) used a novel 0-3 ordinal scale to document the severity of any given hypoechoic area, in which '0' represented normal echogenicity and fi brillar pattern, '1' represented predominantly signs of irregular collagen fi bre pattern coupled with a slightly weakened echo signal, '2' represented signifi cant hypoechoic regions and fi bre irregularity, and '3' represented marked hypoechogenicity with anechoic regions. The length of all observable tears was measured in the longitudinal plane in millimetres ( fi gure 3 ).
The presence or absence of intratendinous calcifi cation was documented, as was irregularity of the cortical bone of the patella.
Hyperosmolar dextrose injection
Injections with 25% dextrose (1 ml 2% lidocaine (20 mg/ml) and 1 ml 50% dextrose (25 g/50 ml) (dextrose monohydrate 500 mg) The neovascularity rating used the following scale: '0' represented no blood vessels visible; '1' indicated mild (one to two vessels extending into the tendon); '2' moderate (three to four neovessels) and '3' marked (more than four vessels extending into the tendon).
group.bmj.com on January 10, 2012 -Published by bjsm.bmj.com Downloaded from in a 2.5 ml syringe) were performed under aseptic conditions using a 27G needle. Abnormal hypoechoic areas and anechoic clefts/foci in the thickened portion of the patellar tendon were the primary target of the intratendinous injection given under ultrasound guidance using a 7-15 MHz Hockey Stick linear array transducer (Phillips USA, Bothell, Washington, USA). Focal areas of pain were also assessed and targeted. The procedure was considered complete when the participant reported no pain in the infrapatellar tendon. The volume of solution injected varied slightly between tendons depending on the degree of resistance, spread of solution within the tendon and the extent of the abnormality. Approximately 0.5 ml was injected at any one site. Between one and three sites were injected during a given treatment session. The tendon was re-imaged following the injection procedure to assess for spread of the dextrose solution and identify any intrasubstance or partial tears that became more conspicuous following the injection.
Follow-up care
The participant was instructed to refrain from activity that would result in a heavy load to the patellar tendon (ie, jumping or running) during the week following the procedure. Participants were cautioned against taking aspirin or other antiinfl ammatory agents to relieve any discomfort. Paracetamolbased analgesia was allowed.
The patient was asked to return for follow-up consultation with ultrasound imaging and possible re-injection every 6 weeks until either the patient's symptoms resolved or no improvement was evident, at which time the treatment was discontinued. Patients were encouraged to not seek additional treatments during the follow-up period.
Data collection
Demographic and baseline status information was collected at the initial consultation. Three visual analogue scale (VAS) pain scores (100 mm) and ultrasound-based outcomes were recorded at baseline and at the fi nal patient consultation (follow-up). 21 The VAS items for pain at rest (VAS1), pain during normal daily activity (VAS2) and pain during or after sporting activity (VAS3) were 'do you have infrapatellar pain at rest; do you have infrapatellar pain during activities of daily living (ADL); and do you have infrapatellar pain during or after sporting or other physical activity', respectively.
Data analysis
Descriptive and mean comparisons of the study data were analysed using SPSS statistical software (copyright 2006, ver- 
RESULTS
Forty-seven patellar tendons from 39 male and six female participants (two had bilateral symptoms) aged 38.3 years (±14.3) participated in this prospective case series. The mean reported symptom duration was 21.8 months (±16.6) before enrolment in the study. The median number of injections needed to treat was four (±3.4; range 2-8) spaced a mean of 6.4 weeks (±5.5 days) apart. The fi nal patient consultation, which included follow-up VAS pain and ultrasound examination, took place 45 weeks (±36) post-treatment initiation. None of the participants sought additional treatments during the follow-up period.
VAS pain scores improved signifi cantly (p<0.01) compared with the baseline status ( table 1 ). The VAS score improved by 49% at rest, 51% during ADL and 50% during sport compared with baseline. Twenty-fi ve participants (53%) reported between 50% and 100% improvement in pain, 19 cases (40%) reported less than 50% improvement and three cases (7%) reported an increase in pain following dextrose injections.
Ultrasound evaluation of the patellar tendon showed structural improvements following dextrose treatment; 12 fewer cases of intratendinous tearing were documented at the 45-week follow-up and eight fewer cases of marked hypoechogenicity ( table 2 ) . VAS pain scores at rest, during ADL and during sport also correlated with changes to echotexture severity (r values 0.306, 0.379 and 0.428, respectively; p<0.05); that is, on average, as pain scores decreased, echotexture improved. There were no changes to tendon thickness or hypoechoic areas at follow-up.
Neovascularity also improved. There was a complete elimination of neovessels in seven cases. The greatest reduction came in cases diagnosed at baseline as 'moderate'. There was also no signifi cant association between the degree of neovascularity and VAS scores at follow-up (r values −0.123, −0.011, 0.056; p≥0.419 for rest, ADL and sport, respectively). There were no changes in any other observed sonographic features. Twenty-one participants showed intratendinous calcifi cation at baseline, which remained unchanged at follow-up.
DISCUSSION
This prospective pilot level case series reports substantial, consistent improvements in pain outcomes at 45 weeks for dextrose prolotherapy as a treatment for patellar tendinopathy, including an association between VAS score improvement and changes on ultrasound evaluation consistent with tissue healing. The mean reduction in pain scores at rest, with ADL and sport ranged from 20 to 39 mm. Whereas the minimal clinical important difference for patellar tendinopathy using a 100 mm VAS is not known, this effect size exceeds that of other chronic pain syndromes using a similar outcome measure. 22 23 These results, in the absence of signifi cant side effects and adverse events, provide a promising indication that dextrose prolotherapy may be effective for patellar tendinopathy. 24 It is the fi rst study to report the effectiveness of dextrose for patellar tendinopathy and suggests that dextrose prolotherapy improves tendon remodelling on ultrasound imaging.
In addition to improvements in pain in the present study, there were signifi cant changes in the tendon structure and vascularity over the course of treatment. The reduction in both the number of tendons with intratendinous tearing and marked (grade 3) hypoechoic regions subsequent to ultrasound-guided dextrose injection treatment suggests tissue remodelling, although histological analysis is needed to confi rm this. The signifi cant positive correlation between hypoechoic severity and pain levels at 45 weeks is indirect evidence that degenerative changes such as collagen fi bre disruption, fi broblast proliferation or altered morphology, and/or the presence of mucoid ground substance is a source of nociceptive pain in patellar tendinopathy. 2 Dextrose is hypothesised to initiate a healing response secondary to very local injury tissue perturbation (cell membrane disruption) following a signifi cant change in osmotic pressure between the extracellular matrix and tendon fi broblasts. 25 Infl ammatory cytokines and chemotactic factors are subsequently released from the cell membrane attracting granulocytes and platelets that in turn release pro-healing growth factors. 26 However, these effects have not been demonstrated compared with control procedures.
Contrary to previous studies, this study did not fi nd an association between neovascularity and pain at the infrapatellar tendon. 19 27 While there was an overall reduction in the number of cases with moderate to marked neovascularity, seven cases reported being asymptomatic despite also having three or more intratendinous blood vessels observed on ultrasound. Previous research using polidocanol, a sclerosing injectant, has reported a strong association between neovascularity, nerve fi bre infi ltration and the presence of specifi c neurotransmitters The echotexture rating used a 0-3 ordinal scale on which '0' represented normal echogenicity and fi brillar pattern, '1' represented predominantly signs of an irregular collagen fi bre pattern coupled with a slightly weakened echo signal, '2' represented signifi cant hypoechoic regions and fi bre irregularity and '3' represented marked hypoechogenicity with anechoic regions. The neovascularity rating used the following scale: '0' represented no blood vessels visible; '1' indicated mild (one to two vessels extending into tendon); '2' moderate (three to four neovessels) and '3' marked (more than four vessels extending into the tendon). group.bmj.com on January 10, 2012 -Published by bjsm.bmj.com Downloaded from for pain in tendinopathy. 28 29 The current study is small, however, and the use of colour Doppler (vs power Doppler) may also have compromised our sensitivity in identifying blood vessels within the tendon. 30 Nevertheless, based on other authors reporting no association between the degree of neovascularity and patient outcomes at the patellar, Achilles and common lateral extensor tendons, it may be reasonable to conclude that neovascularity alone does not reveal an underlying pain mechanism in tendinopathy. [31] [32] [33] Although pain has been associated with neurovascular in-growth, the fact that tendons can be painful or pain-free at any point in their pathogenesis suggests alternative, and currently elusive, causes of pain. 16 The signifi cant association between hypoechoic severity and pain at follow-up does not indicate causation between the improved echo texture and the reduction in pain; future studies would be needed to support this concept further. It is nevertheless of interest that the fi ndings from the present study are in contrast to Cook et al 34 who reported no statistically signifi cant relationship between patellar tendon abnormalities seen on ultrasound and clinical outcomes in elite male athletes. However, differences in the sample population or improvements in ultrasound imaging capabilities may account for these differences.
The degree of pain score improvement in the current study is consistent with that of other therapies for patellar tendinopathy, including eccentric training, 35 glyceryl trinitrate patches 36 and injections of either autologous blood 37 or a sclerosing agent (polidocanol). 19 Outcomes from these approaches appear promising; reported improvements in pain range from 60% to 85%, with high patient satisfaction and return to activity reported. For any injection therapy, the effect of the needle itself may be signifi cant, as indicated by outcomes from percutaneous tenotomy procedures for tendinopathy at the infrapatellar, common lateral elbow extensor and Achilles tendon. [37] [38] [39] 
Limitations and strengths
Limitations include the lack of a control group and blinding of the radiologist performing the injection/ultrasound assessments. The clinical and ultrasound outcome measures, although relevant to clinical progress and the understanding of the pathophysiology of tendinopathy, have not undergone validation or reliability assessment, nor have they been correlated with histopathological analysis. Documentation of intratendinous tearing may be confounded by the presence of hydrophilic glycosaminoglycans in the extracellular space of the tendon; what therefore may appear as a tear with defi nitive anechoic boundaries may be degenerative, severely hypoechoic tissue. In either case, the appearance and size of these anechoic regions could be considered a process of disease, and therefore are noteworthy from the standpoint of tissue characterisation following dextrose injection therapy. The follow-up time period after the fi nal injection was relatively short and no specifi c data on the number of participants who returned to sport are available (although the VAS sport item is meant to refl ect real or hypothetical pain experienced during sport and activity). The strengths of the present study include ultrasound-guided needle placement and injection, a large consistent effect size for pain, and improvement in ultrasound outcomes compared with baseline status.
CONCLUSION
Ultrasound-guided dextrose prolotherapy injections resulted in signifi cant and clinically meaningful reductions in pain in patients with patellar tendinopathy. Tendon structure also improved substantially following injections; changes in hypoechoic severity were signifi cantly correlated with pain outcomes. This suggests that dextrose prolotherapy could be a candidate for non-surgical treatment of refractory patellar tendinopathy. Randomised multidisciplinary effectiveness trials that add validated functional and outcome measures are needed to assess further the utility of dextrose prolotherapy for refractory patellar tendinopathy compared with current therapy.
